<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336133">
  <stage>Registered</stage>
  <submitdate>20/10/2010</submitdate>
  <approvaldate>22/10/2010</approvaldate>
  <actrnumber>ACTRN12610000899044</actrnumber>
  <trial_identification>
    <studytitle>Intralesional Autologous Platelet Rich Plasma Injection Compared to Corticosteroid Injection for the Treatment of Chronic Plantar Fasciitis. A Prospective, Randomised, Controlled Trial.</studytitle>
    <scientifictitle>For patients with chronic plantar fasciitis is the ultrasound guided injection of intralesional autologous platelet rich plasma more effective than perifascial cortisone in improving pain and function?</scientifictitle>
    <utrn>U1111-1117-5482</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Plantar Fasciitis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Three intra-fascial PRP injections (2 mL PRP each) guided by ultrasound, by a medial approach following injection of local anaesthetic into the skin, and at weekly intervals.
Three mL of platelet rich plasma will be obtained using a single step centrifugation procedure and XC-2000 laboratory benchtop centrifuge. Twenty five point five mL of autologous blood will be divided equally between three 8.5 mL ACD BD Vacutainer venous blood collection tubes and centrifuged at 2,000 rpm (447 g) for 10 minutes. The lowest 1 mL of the plasma, the platelet rich plasma (PRP), is then harvested from each tube avoiding contamination by the buffy coat and red cell layers. Two mL will be collected for injection into the patient and 1 mL will be collected for laboratory analysis of platelet numbers. Each sample will be activated with 0.05 mL calcium chloride 10%  per 1 mL plasma.</interventions>
    <comparator>One peri-fascial cortisone injection (1 mL Celestone Chronodose) followed by two non-therapeutic placebo injections of saline guided by ultrasound, by a medial approach following injection of local anaesthetic into the skin, and at weekly intervals.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>American Orthopaedic Foot and Ankle Society (AOFAS) Hindfoot and Ankle Clinical Rating Scale</outcome>
      <timepoint>Baseline and then weekly for the first six weeks and then at three and six months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Foot Function Index (FFI)</outcome>
      <timepoint>Baseline and then weekly for the first six weeks and then at three and six months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Manchester Foot Pain and Disability Index (MFPDI)</outcome>
      <timepoint>Baseline and then weekly for the first six weeks and then at three and six months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Foot Health Status Questionnaire (FHSQ)</outcome>
      <timepoint>Baseline and then weekly for the first six weeks and then at three and six months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>VISA-A Questionnaire</outcome>
      <timepoint>Baseline and then weekly for the first six weeks and then at three and six months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily analgesic requirements (daily patient diary)</outcome>
      <timepoint>Baseline and then weekly for the first six weeks and then at three and six months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plantar fascial thickness on ultrasound scanning</outcome>
      <timepoint>Baseline and then at three and six months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. presenting complaint of plantar heel pain worse on rising in the morning and/or after periods of sitting or lying, which have been present for longer than 6 weeks
2. on examination, site of maximal tenderness at the attachment of the plantar fascia on the medial tubercle of the calcaneus
3. plantar fascial thickness &gt; 4 mm at the area of maximal tenderness
4. failed conservative management of at least 4 weeks duration consisting of calf stretching, tibialis posterior and flexor hallucis longus strengthening, and the use of an off-the-shelf orthotic with heel cut-out and plantar fascial groove</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. previous injections or surgery for heel pain
2. nerve-related symptoms
3. regional pain syndrome
4. achilles tendon pathology
5. rheumatoid arthritis
6. spondyloarthropathy (incl. ankylosing spondylitis, reactive arthritis, enteropathic arthritis, and psoriatic arthritis)
7. diabetes mellitus
8. local infection
9. peripheral vascular disease
10. gout
11. coagulopathy or anti-coagulant therapy
12. pregnancy
13. dysfunction of the knee, ankle, or foot
14. work-related or compensable injury</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation not concealed</concealment>
    <sequence>Computer generated randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>75</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2022</postcode>
    <postcode>2033</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. William Craddock</primarysponsorname>
    <primarysponsoraddress>PO Box 612
Waverley   NSW   2024</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Greg Lovell</othercollaboratorname>
      <othercollaboratoraddress>Department of Orthopaedics
Flinders Medical Centre
Flinders Drive
Bedford Park    SA    5042</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to compare the efficacy of ultrasound guided intralesional injection of autologous platelet rich plasma (PRP) with corticosteroid injection for plantar fasciitis present for more than six weeks that has failed to settle symptomatically with conservative management.</summary>
    <trialwebsite>www.drwilliamcraddock.com.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Australian Institute of Sport (AIS) Ethics Committee</ethicname>
      <ethicaddress>Australian Sports Commission
PO Box 176
Belconnen  ACT   2616</ethicaddress>
      <ethicapprovaldate>19/10/2010</ethicapprovaldate>
      <hrec>20100102</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. William Craddock</name>
      <address>PO Box 612
Waverley   NSW   2024</address>
      <phone>+61 (0)424472376</phone>
      <fax />
      <email>williamc@bigpond.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. William Craddock</name>
      <address>PO Box 612
Waverley   NSW   2024</address>
      <phone>+61 (0)424472376</phone>
      <fax />
      <email>williamc@bigpond.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. William Craddock</name>
      <address>PO Box 612
Waverley   NSW   2024</address>
      <phone>+61 (0)424472376</phone>
      <fax />
      <email>williamc@bigpond.net.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>